Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Open Label, Non-Randomized Study of AZD2281 in the Treatment of Patients With Known BRCA or Recurrent High Grade Serous/ Undifferentiated Tubo-Ovarian Carcinoma and in Known BRCA or Triple Negative Breast Cancer to Determine Response Rate and Correlative Markers of Response

NCT00679783 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00679783
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00679783 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Open Label, Non-Randomized Study of AZD2281 in the Treatment of Patients With Known BRCA or Recurrent High Grade Serous/ Undifferentiated Tubo-Ovarian Carcinoma and in Known BRCA or Triple Negative Breast Cancer to Determine Response Rate and Correlative Markers of Response
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
July 8, 2008
Completion date
July 20, 2022
Enrollment
99 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, ovarian carcinoma